Tilray Brands, Inc. (NASDAQ:TLRY) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Consensus "Hold": Nine brokerages covering Tilray rate the stock a consensus "Hold" (1 sell, 5 hold, 3 buy) with an average 12‑month price objective of $11.20.
• Mixed quarterly results: Q3 EPS of -$0.24 missed consensus (-$0.14) despite revenue beating at $206.7M, and the company remains unprofitable with negative margins and ROE, leaving recovery tied to execution on margins and cash flow.
• Analyst views and catalysts are divided—some firms upgraded TLRY (Roth/MKM, Jefferies with a $24 PT) while others cut targets or stayed cautious (Weiss, ATB Cormark), and sector tailwinds like relaxed CBD enforcement and new product launches are cited as upside drivers.

Shares of Tilray Brands, Inc. (NASDAQ:TLRY - Get Free Report) have earned a consensus recommendation of "Hold" from the nine brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $11.20.

TLRY has been the topic of several research reports. Canaccord Genuity Group began coverage on Tilray Brands in a research report on Tuesday, January 27th. They issued a "hold" rating on the stock. Roth Mkm raised Tilray Brands from a "neutral" rating to a "buy" rating and set a $10.00 target price for the company in a research report on Thursday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tilray Brands in a research note on Wednesday, January 21st. ATB Cormark Capital Markets dropped their target price on Tilray Brands from $9.50 to $9.00 and set a "sector perform" rating on the stock in a report on Thursday. Finally, Zacks Research raised Tilray Brands from a "strong sell" rating to a "hold" rating in a research report on Wednesday, February 11th.

Tilray Brands News Summary

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Roth/MKM upgraded TLRY to Buy (new $10 price target), citing the Q3 results as a catalyst for improved sentiment—this upgrade supports near-term buying interest. Roth upgrade coverage
• Positive Sentiment: Jefferies reiterated a Buy and kept a $24 price target, pointing to strong cannabis sales and better medium‑term visibility; a high PT from a major shop increases upside narratives for investors. Jefferies note
• Positive Sentiment: Regulatory tailwind: reports that the FDA won’t enforce some CBD regulations spurred sector buying, lifting Tilray alongside peers and improving the outlook for CBD revenue. FDA/CBD coverage
• Positive Sentiment: Product/brand news — Tilray Beverages’ Shock Top launched a high‑ABV beer (High Voltage), a growth/innovation signal for the beverages segment that can help top-line recovery over time. Shock Top launch
• Neutral Sentiment: Analyst/deep-dive pieces see TLRY as improving but still mixed: commentary highlights revenue growth, international cannabis up ~73% in Q3, and narrowing losses but cautions on margins, cash flow and M&A execution. This frames TLRY as a recovery story with execution risk. Seeking Alpha analysis
• Neutral Sentiment: Zacks and other commentary call Q3 mixed—revs beat slightly and losses narrowed, but beverage weakness and margin pressure temper bullish cases. Zacks piece
• Negative Sentiment: Earnings miss: TLRY reported Q3 EPS of -$0.24 vs. consensus -$0.14 (revenue ~$206.7M vs. est. ~$201.4M). The EPS shortfall on the call raised concerns about margins and profitability despite top-line improvements. MSN earnings transcript InsiderMonkey transcript
• Negative Sentiment: ATB Cormark trimmed its price target to $9.00 and moved to sector perform, signaling more conservative near‑term expectations and adding selling pressure from cautious analysts. ATB Cormark note

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TLRY. Hilton Head Capital Partners LLC acquired a new position in shares of Tilray Brands in the fourth quarter worth about $38,000. Engineers Gate Manager LP bought a new position in Tilray Brands during the 4th quarter valued at $126,000. Oppenheimer & Co. Inc. acquired a new position in Tilray Brands during the 3rd quarter worth $25,000. Silverlake Wealth Management LLC acquired a new position in Tilray Brands during the 3rd quarter worth $25,000. Finally, Unified Investment Management bought a new stake in shares of Tilray Brands in the 3rd quarter worth about $26,000. 9.35% of the stock is owned by institutional investors and hedge funds.

Tilray Brands Price Performance

Tilray Brands stock opened at $6.55 on Friday. The firm has a fifty day moving average of $7.27 and a 200-day moving average of $10.17. Tilray Brands has a 52-week low of $3.51 and a 52-week high of $23.20. The company has a quick ratio of 1.72, a current ratio of 2.79 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $763.12 million, a P/E ratio of -0.48 and a beta of 2.00.

Tilray Brands (NASDAQ:TLRY - Get Free Report) last posted its earnings results on Wednesday, April 1st. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.10). Tilray Brands had a negative net margin of 156.51% and a negative return on equity of 3.31%. The business had revenue of $206.73 million for the quarter, compared to analyst estimates of $201.35 million. During the same quarter in the previous year, the firm posted ($0.87) EPS. As a group, analysts predict that Tilray Brands will post -0.2 EPS for the current year.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray's product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.